川崎病相关微RNA的功能机制及生物标志物研究进展

doi:10.3969/j.issn.1674-8115.2023.02.017

上海交通大学学报（医学版） ›› 2023, Vol. 43 ›› Issue (2): 256-260.doi: 10.3969/j.issn.1674-8115.2023.02.017

• 综述 • 上一篇

川崎病相关微RNA的功能机制及生物标志物研究进展

冯佳丽¹^,²^,³(), 彭宇³^,⁴, 段君凯¹^,³()

^1.江西省儿童医院心内科，南昌 330006
^2.南昌大学医学部，南昌 330006
^3.江西省卫生健康儿童心血管疾病重点实验室，南昌 330006
^4.江西省儿童医院风湿免疫科，南昌 330006

收稿日期:2022-08-22 接受日期:2023-01-15 出版日期:2023-02-28 发布日期:2023-02-28
通讯作者: 段君凯 E-mail:316240143@qq.com;yeduanjk@163.com
作者简介:冯佳丽（1995—），女，硕士生；电子信箱：316240143@qq.com。
基金资助:
江西省重点研发计划项目(911125321037)

Progress in functional mechanisms and biomarkers of miRNA related to Kawasaki disease

FENG Jiali¹^,²^,³(), PENG Yu³^,⁴, DUAN Junkai¹^,³()

^1.Department of Cardiology, Jiangxi Provincial Children's Hospital, Nanchang 330006, China
^2.Medical College of Nanchang University, Nanchang 330006, China
^3.JXHC Key Laboratory of Children's Cardiovascular Diseases, Nanchang 330006, China
^4.Department of Rheumatology, Jiangxi Provincial Children's Hospital, Nanchang 330006, China

Received:2022-08-22 Accepted:2023-01-15 Online:2023-02-28 Published:2023-02-28
Contact: DUAN Junkai E-mail:316240143@qq.com;yeduanjk@163.com
Supported by:
Key Research and Development Program of Jiangxi Province(911125321037)

摘要/Abstract

摘要：

川崎病是一种以全身血管炎为主要病变的急性发热出疹性小儿疾病，为儿童后天性心脏病最常见的病因。该病病因尚不明确，发病机制仍有待探索。部分川崎病病例由于临床表现不典型易被误诊，未经有效治疗的患者并发冠状动脉病变的风险增加。因此，及时诊断川崎病与预测冠状动脉病变对川崎病及早治疗、改善预后具有重大意义。微RNA（miRNA）在生物体的各种生命过程中发挥着重要作用，同时miRNA表达失调参与众多疾病的发生、发展。目前研究显示，miRNA可辅助疾病的诊断、预后评估和大规模人群筛查，作为新型生物标志物具有潜在的临床应用前景。近期研究发现，miRNA与川崎病发病机制相关，其表达失调将导致川崎病患者的免疫失衡及血管损伤。另有部分研究表明，循环miRNA可作为川崎病潜在的生物标志物，主要聚焦于川崎病早期诊断及疗效预测。目前的研究尚处于探索阶段，需要更多的临床研究去验证川崎病相关miRNA的早期诊断及预测效能。该文就近年来miRNA在川崎病中的功能机制及生物标志物研究进行综述。

关键词: 川崎病, 微RNA, 生物标志物, 发病机制, 诊断, 疗效预测

Abstract:

Kawasaki disease is an acute febrile exanthema pediatric disease with systemic vasculitis as the main lesion, which is the most common cause of acquired heart disease in children. The etiology of the disease is not clear, and the pathogenesis remains to be explored. Some cases of Kawasaki disease are prone to misdiagnosis due to atypical clinical presentations, and patients who have not been effectively treated are at increased risk of coronary artery lesion. Therefore, timely diagnosis of Kawasaki disease and prediction of coronary artery lesion have great significance for early treatment and prognosis of Kawasaki disease. MiRNA plays an important role in various life processes of organisms, and dysregulation of miRNA is involved in the occurrence and development of many diseases. Current studies have shown that miRNA can assist in the diagnosis, prognosis assessment and large-scale population screening of diseases, and has potential clinical application prospects as a novel biomarker. Recent studies have found that miRNA is associated with the pathogenesis of Kawasaki disease, and expression dysregulation will lead to immune imbalance and vascular damage in patients with Kawasaki disease. Other studies have shown that circulating miRNA can be used as a potential biomarker of Kawasaki disease, mainly focusing on early diagnosis and efficacy prediction of Kawasaki disease. The current research is still at the exploratory stage, and more clinical studies are needed to verify the early diagnosis and prediction efficacy of miRNA related to Kawasaki disease. This article reviews the functional mechanism and biomarkers of miRNA in Kawasaki disease in recent years.

Key words: Kawasaki disease, miRNA, biomarker, pathogenesis, diagnosis, efficacy prediction

中图分类号:

R725.4

冯佳丽, 彭宇, 段君凯. 川崎病相关微RNA的功能机制及生物标志物研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(2): 256-260.

FENG Jiali, PENG Yu, DUAN Junkai. Progress in functional mechanisms and biomarkers of miRNA related to Kawasaki disease[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 256-260.

参考文献 41

1	孙锟, 沈颖, 黄国英. 小儿内科学[M]. 6版. 北京: 人民卫生出版社, 2020: 303.
	SUN K,SHEN Y,HUANG G Y.Pediatric Internal Medicine[M].Beijing: People's Medical Publishing House, 2020: 303.
2	KIM G B, PARK S, EUN L Y, et al. Epidemiology and clinical features of Kawasaki disease in south Korea, 2012‒2014[J]. Pediatr Infect Dis J, 2017, 36(5): 482-485.
3	LEONG K, KANE J M, JOY B F. Acquired cardiac disease in the pediatric intensive care unit[J]. Pediatr Ann, 2018, 47(7): e280-e285.
4	SHUKLA G C, SINGH J, BARIK S. MicroRNAs: processing, maturation, target recognition and regulatory functions[J]. Mol Cell Pharmacol, 2011, 3(3): 83-92.
5	HA M J, KIM V N. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol, 2014, 15(8): 509-524.
6	KINSER H E, PINCUS Z. MicroRNAs as modulators of longevity and the aging process[J]. Hum Genet, 2020, 139(3): 291-308.
7	SALIMINEJAD K, KHORRAM KHORSHID H R, SOLEYMANI FARD S, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods[J]. J Cell Physiol, 2019, 234(5): 5451-5465.
8	CORTEZ M A, CALIN G A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases[J]. Expert Opin Biol Ther, 2009, 9(6): 703-711.
9	CHEN X, BA Y, MA L J, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008, 18(10): 997-1006.
10	LIAO C, YIN A H, PENG C F, et al. Noninvasive prenatal diagnosis of common aneuploidies by semiconductor sequencing[J]. Proc Natl Acad Sci USA, 2014, 111(20): 7415-7420.
11	范雪, 徐明国. 川崎病发病机制及治疗研究进展[J]. 中国实用儿科杂志, 2021, 36(5): 339-344.
	FAN X,XU M G.Research progress in the pathogenesis and treatment of Kawasaki disease[J].Chinese Journal of Practical Pediatrics,2021,36(5):339-344.
12	NI F F, LI C R, LI Q, et al. Regulatory T cell microRNA expression changes in children with acute Kawasaki disease[J]. Clin Exp Immunol, 2014, 178(2): 384-393.
13	LUO Y, YANG J, ZHANG C, et al. Up-regulation of miR-27a promotes monocyte-mediated inflammatory responses in Kawasaki disease by inhibiting function of B10 cells[J]. J Leukoc Biol, 2020, 107(1): 133-144.
14	LI Z Y, JIANG J, TIAN L, et al. A plasma miR-125a-5p as a novel biomarker for Kawasaki disease and induces apoptosis in HUVECs[J]. PLoS One, 2017, 12(5): e0175407.
15	LIU C W, YANG D G, WANG H, et al. MicroRNA-197-3p mediates damage to human coronary artery endothelial cells via targeting TIMP3 in Kawasaki disease[J]. Mol Cell Biochem, 2021, 476(12): 4245-4263.
16	NAKAOKA H, HIRONO K, YAMAMOTO S, et al. MicroRNA-145-5p and microRNA-320a encapsulated in endothelial microparticles contribute to the progression of vasculitis in acute Kawasaki disease[J]. Sci Rep, 2018, 8(1): 1016.
17	CHU M P, WU R Z, QIN S S, et al. Bone marrow-derived microRNA-223 works as an endocrine genetic signal in vascular endothelial cells and participates in vascular injury from Kawasaki disease[J]. J Am Heart Assoc, 2017, 6(2): e004878.
18	ZHANG Y, WANG Y F, ZHANG L, et al. Reduced platelet miR-223 induction in Kawasaki disease leads to severe coronary artery pathology through a miR-223/PDGFRβ vascular smooth muscle cell axis[J]. Circ Res, 2020, 127(7): 855-873.
19	HE M, CHEN Z, MARTIN M, et al. MiR-483 targeting of CTGF suppresses endothelial-to-mesenchymal transition: therapeutic implications in Kawasaki disease[J]. Circ Res, 2017, 120(2): 354-365.
20	RONG X, GE D H, SHEN D P, et al. MiR-27b suppresses endothelial cell proliferation and migration by targeting Smad7 in Kawasaki disease[J]. Cell Physiol Biochem, 2018, 48(4): 1804-1814.
21	GORELIK M, CHUNG S A, ARDALAN K, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease[J]. Arthritis Rheumatol, 2022, 74(4): 586-596.
22	RIZK S R Y, EL SAID G, DANIELS L B, et al. Acute myocardial ischemia in adults secondary to missed Kawasaki disease in childhood[J]. Am J Cardiol, 2015, 115(4): 423-427.
23	WU R Z, SHEN D P, SOHUN H, et al. miR‑186, a serum microRNA, induces endothelial cell apoptosis by targeting SMAD6 in Kawasaki disease[J]. Int J Mol Med, 2018, 41(4): 1899-1908.
24	ZHANG X F, XIN G D, SUN D J. Serum exosomal miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers for the diagnosis of Kawasaki disease and the prediction of therapeutic outcomes of intravenous immunoglobulin therapy[J]. Exp Ther Med, 2018, 16(3): 2420-2432.
25	LV H F, SUN X Q, ZHOU H X, et al. Diagnostic value of miRNA-122 in Kawasaki disease[J]. Eur Rev Med Pharmacol Sci, 2020, 24(21): 11222-11226.
26	NING Q Q, CHEN L Q, SONG S R, et al. The platelet microRNA profile of Kawasaki disease: identification of novel diagnostic biomarkers[J]. Biomed Res Int, 2020, 2020: 9061568.
27	WENG K P, CHENG C F, CHIEN K J, et al. Identifying circulating microRNA in Kawasaki disease by next-generation sequencing approach[J]. Curr Issues Mol Biol, 2021, 43(2): 485-500.
28	YAN J, WANG H, GAO L X. Diagnostic value of serum miR-1 in patients with acute Kawasaki disease[J]. Clin Lab, 2019, 65(7). DOI:10.7754/Clin.Lab.2019.190339.
29	SAITO K, NAKAOKA H, TAKASAKI I, et al. MicroRNA-93 may control vascular endothelial growth factor A in circulating peripheral blood mononuclear cells in acute Kawasaki disease[J]. Pediatr Res, 2016, 80(3): 425-432.
30	SHIMIZU C, KIM J, STEPANOWSKY P, et al. Differential expression of miR-145 in children with Kawasaki disease[J]. PLoS One, 2013, 8(3): e58159.
31	ZHANG R, WU L, ZHANG H J, et al. Expression levels of plasma miRNA-21 and NT-proBNP in children with Kawasaki disease and their clinical significance[J]. Eur Rev Med Pharmacol Sci, 2020, 24(24): 12757-12762.
32	ZHENG X L, LI Y F, YUE P, et al. Diagnostic significance of circulating miRNAs in Kawasaki disease in China: current evidence based on a meta-analysis[J]. Medicine, 2021, 100(6): e24174.
33	JIA H L, LIU C W, ZHANG L, et al. Sets of serum exosomal microRNAs as candidate diagnostic biomarkers for Kawasaki disease[J]. Sci Rep, 2017, 7: 44706.
34	KIBATA T, SUZUKI Y, HASEGAWA S, et al. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin[J]. Int J Cardiol, 2016, 214: 209-215.
35	LI X, CHEN Y, TANG Y J, et al. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases[J]. Eur J Pediatr, 2018, 177(8): 1279-1292.
36	ZHANG W, WANG Y, ZENG Y W, et al. Serum miR-200c and miR-371-5p as the useful diagnostic biomarkers and therapeutic targets in Kawasaki disease[J]. Biomed Res Int, 2017, 2017: 8257862.
37	RONG X, JIA L H, HONG L L, et al. Serum miR-92a-3p as a new potential biomarker for diagnosis of Kawasaki disease with coronary artery lesions[J]. J of Cardiovasc Trans Res, 2017, 10(1): 1-8.
38	LI S C, HUANG L H, CHIEN K J, et al. MiR-182-5p enhances in vitro neutrophil infiltration in Kawasaki disease[J]. Mol Genet Genomic Med, 2019, 7(12): e990.
39	WANG Y F, LIAN X L, ZHONG J Y, et al. Serum exosomal microRNA let-7i-3p as candidate diagnostic biomarker for Kawasaki disease patients with coronary artery aneurysm[J]. IUBMB Life, 2019, 71(7): 891-900.
40	WANG Y F, LU Z L, FU L Y, et al. The miRNA-608 rs4919510 G>C polymorphism confers reduce coronary injury of Kawasaki disease in a southern Chinese population[J]. Biosci Rep, 2019, 39(5): BSR20181660.
41	FU L Y, XU Y F, YU H Y, et al. Association study of miR-149, miR-196a2, and miR-499a polymorphisms with coronary artery aneurysm of Kawasaki disease in southern Chinese population[J]. J Gene Med, 2022, 24(4): e3405.

[1]	后书敏, 邵静波. TdT阴性的淋巴母细胞淋巴瘤/急性淋巴细胞白血病临床特点、诊断及预后研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(1): 120-124.
[2]	蒋文群, 侯品品, 陈燕, 贾锋, 张晓华, 高丽, 胡琴. 急性缺血性脑卒中患者血清肾胺酶表达特征及临床意义[J]. 上海交通大学学报（医学版）, 2023, 43(1): 29-35.
[3]	黄治物, 吴皓. 年龄相关性听力损失研究进展与临床干预策略[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1182-1187.
[4]	张琳程, 钟华. 结节病的发病机制与临床治疗研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(7): 931-938.
[5]	何冬梅, 杨驰. 下颌骨髁突骨折的诊治方案：基于上海交通大学医学院附属第九人民医院颞下颌关节中心的经验[J]. 上海交通大学学报（医学版）, 2022, 42(6): 695-701.
[6]	何冬梅, 杨驰. 颞下颌关节强直的诊治方案：基于上海交通大学医学院附属第九人民医院颞下颌关节中心的经验[J]. 上海交通大学学报（医学版）, 2022, 42(6): 702-708.
[7]	张善勇, 杨驰. 颞下颌关节骨关节炎的诊治方案：基于上海交通大学医学院附属第九人民医院颞下颌关节中心的经验[J]. 上海交通大学学报（医学版）, 2022, 42(6): 709-716.
[8]	吕拥芬, 李嫔. 21-羟化酶缺乏症的分子诊断及临床意义[J]. 上海交通大学学报（医学版）, 2022, 42(5): 557-561.
[9]	张梦吉, 黄琳, 李峥, 马卓然, 魏霖, 袁安彩, 胡刘华, 张薇, 钱昆, 卜军. 基于人群大队列探索心脑血管疾病相关血浆代谢组学特征[J]. 上海交通大学学报（医学版）, 2022, 42(3): 259-266.
[10]	陈威存, 苑影, 柯碧莲. 近视相关非编码RNA的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(3): 369-374.
[11]	陈仪婷, 赵安达, 李荣, 康文慧, 李生慧. 循环外泌体微RNA在支气管哮喘中的作用综述[J]. 上海交通大学学报（医学版）, 2022, 42(3): 375-380.
[12]	赵久红, 童佳婷, 沈郅珺, 吕叶辉. 环状RNA与氧化应激互作机制的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(3): 393-399.
[13]	邹弋华, 彭婕, 赵培泉. 先天性视盘凹陷性异常的临床特征与治疗研究进展[J]. 上海交通大学学报(医学版), 2022, 42(2): 230-234.
[14]	袁咏梅, 程晓丹, 孙家安, 常东歌, 何莹莹, 刘畅. lncRNA NEAT1通过miR-377-3p/Wnt通路影响ox-LDL诱导的人血管平滑肌细胞增殖、侵袭迁移[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1534-1541.
[15]	顾殊能, 吴鹏飞, 武育蓉. 先天性血管环的产前产后诊治现状[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1620-1626.

川崎病相关微RNA的功能机制及生物标志物研究进展

Progress in functional mechanisms and biomarkers of miRNA related to Kawasaki disease

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics